Johnson & Johnson's TAR-200 Achieves Remarkable Response Rates In Certain Bladder Cancer Cases
27/4 09:39
(RTTNews) - Johnson & Johnson (JNJ)today announced new data from Cohort 2 of the pivotal Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain types of bladder cancer. The study shows more than 82 percent of patients ac...